Skip to content
Desogestrel
Cyclessa (desogestrel) is a small molecule pharmaceutical. Desogestrel was first approved as Desogen on 1992-12-10. It is used to treat acne vulgaris, endometriosis, and menstruation disturbances in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Combinations
Cyclessa (generic drugs available since 1999-08-12, discontinued: Desogen, Emoquette, Mircette, Ortho-cept)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Desogestrel
+
Ethinyl estradiol
Tradename
Company
Number
Date
Products
CYCLESSAAspen GlobalN-021090 RX2000-12-20
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bekyree ANDA2021-12-18
emoquetteANDA2021-01-20
enskyce ANDA2020-02-04
isibloomANDA2023-03-15
kalligaANDA2021-02-01
karivaANDA2017-04-30
mircetteANDA2017-04-30
pimtrea ANDA2018-11-26
reclipsenANDA2023-06-07
simliyaANDA2021-02-06
Show 3 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acne vulgarisEFO_0003894D000152L70
endometriosisEFO_0001065D004715N80
menstruation disturbancesHP_0400007D008599N91.5
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03A: Hormonal contraceptives for systemic use
— G03AA: Progestogens and estrogen systemic contraceptives, fixed combinations
— G03AA09: Desogestrel and ethinylestradiol
— G03AB: Progestogens and estrogens systemic contraceptives, sequential preparations
— G03AB05: Desogestrel and ethinylestradiol
— G03AC: Progestogen systemic hormonal contraceptives
— G03AC09: Desogestrel
— G03F: Progestogens and estrogens in combination
— G03FB: Progestogens and estrogens, sequential preparations
— G03FB10: Desogestrel and estrogen
HCPCS
No data
Clinical
Clinical Trials
87 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NocturiaD053158R35.1—7162427
Nocturnal enuresisD053206N39.44——37414
Hemophilia aD006467EFO_0007267D661——225
HemorrhageD006470MP_0001914R5811—2—4
HypothermiaD007035HP_0002045T68———112
Blood coagulation disordersD001778EFO_0009314D68.9———112
Sickle cell anemiaD000755EFO_0000697D57———112
Postoperative hemorrhageD019106———2—2
Cardiac surgical proceduresD006348———1—1
Aortic valve stenosisD001024EFO_0000266Q25.1———1—1
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal colicD056844EFO_1001412N23——1—12
Neurogenic diabetes insipidusD020790HP_0000863——1—12
LeptospirosisD007922EFO_0007344A27—11——1
PainD010146EFO_0003843R52——1——1
Obstructive sleep apneaD020181EFO_0003918G47.33——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.911———2
Cerebral hemorrhageD002543—1———1
EcchymosisD004438HP_0000978—1———1
Overactive urinary bladderD053201EFO_1000781N32.81—1———1
Colorectal neoplasmsD015179—1———1
Breast neoplasmsD001943EFO_0003869C50—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I101————1
DyspneaD004417HP_0002094R06.01————1
TachycardiaD013610HP_0001649R00.01————1
Prostatic neoplasmsD011471C611————1
AtherosclerosisD050197EFO_0003914I25.11————1
Intracranial arteriosclerosisD002537EFO_1000860I67.21————1
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes insipidusD003919E23.2————22
Wounds and injuriesD014947T14.8————11
HemodilutionD006438————11
MenorrhagiaD008595N92.0————11
Hematologic diseasesD006402EFO_0005803D75.9————11
Blood platelet disordersD001791————11
Von willebrand diseasesD014842D68.0————11
Drug-related side effects and adverse reactionsD064420T88.7————11
Liver cirrhosisD008103EFO_0001422K74.0————11
Nephrogenic diabetes insipidusD018500N25.1————11
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDESOGESTREL
INNdesogestrel
Description
Desogestrel is a 17beta-hydroxy steroid and a terminal acetylenic compound. It has a role as a contraceptive drug, a progestin and a synthetic oral contraceptive.
Classification
Small molecule
Drug classestrogens; progestins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC
Identifiers
PDB—
CAS-ID54024-22-5
RxCUI22656
ChEMBL IDCHEMBL1533
ChEBI ID4453
PubChem CID40973
DrugBankDB00304
UNII ID81K9V7M3A3 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,556 documents
View more details
Safety
Black-box Warning
Black-box warning for: Emoquette, Enskyce , Isibloom, Kalliga, Volnea
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
8,845 adverse events reported
View more details